Clinical Trial Opportunities for More Patients -DCT Japan Expands Partnerships with Medical Institutions in Seven Disease Areas-

DCT Japan Inc. (Head Office: Chuo-ku, Tokyo; President: Shinsuke Muto; hereinafter “DCT Japan”) is the first company in Japan specializing in Decentralized Clinical Trials (hereinafter “DCT”). DCT Japan provides comprehensive solutions related to DCTs, including the establishment of a nationwide network of visiting nurses for home clinical trials and a network of satellite sites to support patient recruitment.

DCT Japan is pleased to announce that it has entered into a clinical cooperation agreement with multiple medical institutions with a large number of eligible patients in disease areas where patient recruitment is particularly challenging, to further expand satellite site services.

Background

DCT is a system that allows subjects to participate in clinical trials without having to visit the clinical trial site, by utilizing telemedicine, home nursing, and IoT technology. Based on the philosophy of “Patient Centricity,” the use of DCT has been expanding not only in Japan, but globally in recent years.

In Japan, drug lag and drug loss continue to be major issues, and DCT is attracting attention as an important means of building a clinical trial delivery system that meets international standards. In addition, clinical trial pipelines in recent years have shifted from lifestyle-related diseases to oncology, rare diseases, and central nervous system (CNS) diseases, and the small number of patients in these areas pose significant challenges in the conduct of clinical trials. Against this backdrop, the introduction of DCTs is expected to increase patient access to healthcare.

DCT Japan Initiatives

DCT Japan has entered into a clinical cooperation agreement with multiple medical institutions that are expected to have a high concentration of patients in areas where accessibility needs to be improved due to regional disparities in the availability of specialists and disease-specific issues such as physical deterioration and difficulty in visiting clinics. The agreement supports the satellite site initiative for the implementation of DCT.

Target Diseases

• Systemic Lupus Erythematosus (SLE)
• Alzheimer’s disease
• Parkinson’s disease
• Amyotrophic lateral sclerosis (ALS)
• Cancer
• Muscular dystrophy
• Myasthenia gravis

Through this initiative, DCT Japan will enable faster patient recruitment for clinical trials targeting these diseases, leading to shorter clinical trial durations and also more opportunities for patients to participate in clinical trials.

Future Prospects

DCT Japan plans to further expand the range of target diseases and strengthen its network of affiliated medical institutions. Through collaboration with pharmaceutical companies and CROs, DCT Japan will contribute to the development of Japanese healthcare by developing a system to meet diverse clinical trial needs, shortening the duration of clinical trials, and ultimately bringing new drugs to market earlier.

—

About DCT:

DCT (Decentralized Clinical Trial) is a clinical trial that does not depend on patient visits to trial sites,by utilizing ,home nursing care by nurses, telemedicine and IoT technologies such as wearable devices . This approach reduces the burden of site visits caused by patients’ health status and physical distance from the trial site, improves patient enrollment and reduces trial costs.

About DCT Japan Inc: 

DCT Japan Inc. was established in February 2022 as part of the Integrity Healthcare Group and is the first company in Japan specializing in decentralized clinical trials. The company provides comprehensive solutions related to DCT, focusing on home nursing visits, IT solutions such as online medical systems, as well as patient recruitment by establishing a network of satellite sites. https://dctj.co.jp/en/

For related inquiries, please contact
DCT Japan Inc. Public Relations: pr＠dctj.co.jp